

Webinar on IMI2 - Call 23 webinar: Accelerating biomarker discovery to support therapeutics development for neurodegenerative diseases

Participant list

26.06.2020

Name	Surname	Organisation	Country	E-mail address	Potential contribution to the project in terms of expertise, resources and activities.
Ilaria	Allora	Politecnico di Torino	Italy	ilaria.allora@polito.it	
Zuzanna	Andrzejewska	Institut Imagine	France	zuzanna.andrzejewska@institutimaginaire.org	genetic diseases models, pipelines for drug/biomarkers discovery/validation, genetic screening, single-cell multiOMICs, AI
Agustin	Arasanz Duque	VHIR	Spain	agustin.arasanz@vhir.org	Project Management
Dimitrios	Athanasίου	WORLD DUCHENNE ORGANIZATION / UPPMD	Greece	DATHAX@GMAIL.COM	Rare diseases
Dana	Azar	Hôpital Fondation A. de Rothschild	France	dazar@for.paris	The hospital is specialized in ophthalmology and neurosciences
M ^a Pilar	Belenguer	TETRANEURON	Spain	pilar.belenguer@tetraeuron.com	
Ana	Bengoetxea	Université Libre de Bruxelles	Belgium	ana.bengoetxea@ulb.be	Biomarker for early detection of sensorimotor deficits in Parkinson Disease
Sarah	Berrocso	IDIVAL	Spain	proyectoseuropeos@idival.org	

Name	Surname	Organisation	Country	E-mail address	Potential contribution to the project in terms of expertise, resources and activities.
Anna	bersano	Fondazione IRCCS istituto Neurologico Carlo Besta	Italy	anna.bersano@istituto-besta.it	Similar projects
Charles	Betz	Luxinnovation	Luxembourg	charles.betz@luxinnovation.lu	Connect to participants from Luxembourg (public and private)
Shayon	Bhattacharya	University of Limerick	Ireland	shayon.bhattacharya@ul.ie	I am actively working on computational modelling of neurodegenerative proteins and assemblies.
Florence	Bietrix	Eatris	Netherlands	florencebietrix@eatris.eu	
Thomas	Birngruber	Joanneum Research	Austria	thomas.birngruber@joanneum.at	High level sampling techniques in the brain (www.openflowmicroperfusion.com) metabolomics and bioanalytical expertise
Jan-Willem	Boiten	Lygature	Netherlands	janwillem.boiten@lygature.org	Program management, data infrastructure experience, communication
Francesca	Borrelli	University of Luxembourg	Luxembourg	francescaborrelli@gmail.com	automated platform
Isabelle	Bos	Maastricht University	Netherlands	isabelle.bos@maastrichtuniversity.nl	Clinical expertise on Alzheimer's disease, knowledge and skills on data harmonization

Name	Surname	Organisation	Country	E-mail address	Potential contribution to the project in terms of expertise, resources and activities.
Marieke	Bruinsma	Mimetas - the Organ-on-a-Chip company	Netherlands	m.bruinsma@mimetas.com	Organ-on-a-chip, high-throughput screening, 3D biological models (healthy and diseased), microfluidics
Martha	Brumfield	Dr.	United States	martha.brumfield@gmail.com	Experience with biomarker and novel methodology development in neuroscience and expertise with data curation and modeling
Ana Belen	Caballero	UNIVERSITAT DE BARCELONA	Spain	ana.caballero@ub.edu	Functionalization of nanoparticles to interact with amyloid proteins
Jenny	Camaradou	EUPATI trainee	United Kingdom	jenny@rethinkfunding.co.uk	patient advocacy, expertise, AI VC fund, project management
Laura	Carrasco	PARKINSON MADRID ASSOCIATION	Spain	direccion@parkinsonmadrid.org	WITH MORE THAN 1.500 MEMBERS. SOCIAL AND REHABILITATION DIRECT ATTENTION. AWARENESS AND ADVOCACY. VALIDATION TECHNOLOGY
Paula	Certuche	IDOM	Spain	pcertuchev@idom.com	Solutions to public and private healthcare systems, Data analysis and data science, Information technology Infrastructure,
Jessica	Cibrian	FI Group	Spain	jessica.cibrian@fi-group.com	Coordination & Consortium Management. Communication, Dissemination & Exploitation Partner
Tzali	Cnaani	Carmel Diagnostics Ltd.	Israel	tzali@carmel-diagnostics.com	We developed and validated a system measuring oxidative stress, a major factor in AD, PA, ALS pathogenesis. important biomarker

Name	Surname	Organisation	Country	E-mail address	Potential contribution to the project in terms of expertise, resources and activities.
Eleanor	Coffey	Åbo Akademi University	Finland	ecoffey@abo.fi	HT clinical proteomics biomarker assay for neurodegenerative disease from patient blood.
Jean-Christophe	Corvol	ICM	France	jean-christophe.corvol@aphp.fr	PD samples and cohorts (French national NS-PARK cohort)
Cristina	Cuscó	Vall d'Hebron Institute of Research	Spain	cristina.cusco@vhir.org	
Ilse	Custers	Lygature	Netherlands	ilse.custers@gmail.com	HEOR on heel prick screening programs, diagnostics (Personalised Medicine). Rare diseases network.
Eleanor	Dawson	ttopstart	Netherlands	eleanormarydawson@gmail.com	Consultancy, strategic advice, consortium building
Marta	de Diego	CDTI	Spain	marta.dediego@cdti.es	
Yoram	Devary	ISK Ltd	Israel	yoramdevary@gmail.com	We bring patents of novel human brain biomarkers discovered by our platform. These biomarkers control central brain functions
Mara	Diaconu	Norwegian University of Science and Technology (NTNU)	Norway	mara.diaconu@ntnu.no	Expertise in advanced in vitro and computational modelling of neuroplasticity in healthy and perturbed conditions.
Lauranne	Duquenne	NeurATRIS	France	lauranne.duquenne@cea.fr	

Name	Surname	Organisation	Country	E-mail address	Potential contribution to the project in terms of expertise, resources and activities.
Stanley	Durrleman	Paris Brain Institute	France	stanley.durrleman@icm-institute.org	data management, data analytics for neuroscience data
Anna	Dziubczynska-Pytko	IPPT PAN	Poland	anna.dziubczynska-pytko@kpk.gov.pl	
Dubravka	Eliasson	University of Gothenburg	Sweden	dubravka.eliasson@gu.se	
Kirsten	Emmert	Kiel University	Germany	k.emmert@neurologie.uni-kiel.de	The team in Kiel can help explore digital biomarkers (mainly using wearables), offer clinical expertise in PD & patient access.
Leonidas	Fotiadis	akeso-rheumazein	Greece	fotiadisleonidas@gmail.com	
Audrey	Gabelle	CHU	France	audreygabelle@hotmail.com	Clinical biobanks, Patients cohorts, Proteomics technics, predicting models, IA, e-tool
Annemieke	Geluk	Academisch Ziekenhuis Leiden (LUMC)	Netherlands	ageluk@lumc.nl	Experience in Immunology & Biomarkers (immune, transcriptomic) for Dx and predicting nerve damage in Leprosy; Dx test developmnt
Mireia	Giménez	LEITAT	Spain	mgimenez@leitat.org	Wide expertise in preclinical model, biomarker discovery, target validation, 3D models, neurodegenerative diseases
Bridget	Glaysheer	Modus Research and Innovation	United Kingdom	bridget@modus.ltd	
Geraldine	Gouzer	Paris Brain Institute	France	geraldine.gouzer@icm-institute.org	Clinical research and cohorts of PD + experts in multimodal data analysis

Name	Surname	Organisation	Country	E-mail address	Potential contribution to the project in terms of expertise, resources and activities.
Erika	Györvary	CSEM	Switzerland	egv@csem.ch	organ-on-chip technology and biosensors
Martin	Hofmann-Apitius	Fraunhofer Society	Germany	martin.hofmann-apitius@scai.fraunhofer.de	experience with NDD biomarkers, NDD data & knowledge management, cutting edge AI technologies in the NDD arena; leadership
Eran	Hornstein	Dr.	Israel	eran.hornstein@weizmann.ac.il	molecular medicine systems biology genetics and neuropathology expertise, Weizmann Institute infrastructure
Elizabeth	Hufton	University of Nottingham	United Kingdom	Elizabeth.Hufton@nottingham.ac.uk	
Rafael C	Jimenez	ARUK	United Kingdom	rafael.jimenez@alzheimersresearchuk.org	Expertise managing projects for the validation of digital biomarkers for early detection of neurodegenerative diseases
Rita	Juneja	Pharmaceutical Research and Manufacturers Association	Thailand	rita@prema.or.th	To find Thai researchers and form a partnership for research projects in IMI platform leading to new discoveries
Joanna	Kaldrack	MDC	Germany	joanna.kaldrack@mdc-berlin.de	
Nachiket	Kashikar	Apollo Life Sciences GmbH	Germany	nachiket.kashikar@apollo-lifesciences.de	APLS brings a novel transcriptomics technology that allows quantification of up to 100 genes in situ at a single-cell resolution
donal	Killackey	SSPC - Pharmaceutical	Ireland	donal.killackey@ul.ie	Focus on synaptopathies as key feature of neurodevelopmental

Name	Surname	Organisation	Country	E-mail address	Potential contribution to the project in terms of expertise, resources and activities.
		Research Centre Ireland			diseases; understand genetic/non-genetic factors contribute.
Laura	Korsakova	Neurostrain	Lithuania	laura@neurostrain.lt	
Dirk	Lanens	University of Antwerp	Belgium	dirk.lanens@uantwerpen.be	Field of research
Gael	Le Douaron	UPEC	France	gael.le-douaron@u-pec.fr	Expertise in glycobiology, neurodegenerative disease. Cell culture, biochemistry, molecular biology, OMICS, histology.
Jessica	Lee	Medicines Discovery Catapult	United Kingdom	jessica.lee@md.catapult.org.uk	
Volker	Liebenberg	Illumina Inc.	Germany	vliebenberg@illumina.com	Genomic sequencing, Biomarker discovery, IVD development
Erno	Lindfors	LifeGlimmer GmbH	Germany	lindfors@lifeglimmer.com	Biobank data management, machine learning, pathway analysis, molecular dynamics simulation, UI development, project management
Maria	Lindqvist	Karolinska institute	Sweden	maria.lindqvist@stud.ki.se	
Mitja	Lustrek	Jozef Stefan Institute, Department of Intelligent Systems	Slovenia	mitja.lustrek@ijs.si	Applied artificial intelligence in health, machine learning / data mining, experience with neurodegenerative diseases

Name	Surname	Organisation	Country	E-mail address	Potential contribution to the project in terms of expertise, resources and activities.
Lucia	Malaguarnera	University of Catania	Italy	lucmal@unict.it	
Monica	Marchese	LIH/IBBL (Integrated Biobank of Luxembourg)	Luxembourg	monica.marchese@ibbl.lu	Dedicated Group with expertise in Biomarker Validation operating in an ISO17025 accredited setting
Mayca	Marin	Asociación Parkinson Madrid	Spain	proyectos@parkinsonmadrid.org	Expertise IMI and H2020. Patients needs. Testing technology. Studies aimed to patients, caregivers and socio health
Marta	Marin	Instituto de Salud Carlos III	Spain	mmarin@eu-isciii.es	
Sara	Mas Assens	VHIR	Spain	sara.mas@vhir.org	
Marjorie	Monleau	Ad'Occ	France	marjorie.monleau@agence-adocc.com	
Daniel	Mosquera	Qubiotech Health Intelligence SL	Spain	daniel@qubiotech.com	Neurocloud: a cloud CDS aimed to help imaging physicians and neurologists in the diagnostic of neurodegenerative diseases
Sophie	Mourgues	CHU of Toulouse	France	mourgues.s@chu-toulouse.fr	
Winfried	Neuhaus	AIT	Austria	winfried.neuhaus@ait.ac.at	
Christa	Noehammer	AIT Austrian Institute of Technology GmbH	Austria	christa.noehammer@ait.ac.at	Biomarker discovery/validation (e.g. DNA methylation, autoantibodies, EVs/exosomes), bioinformatics, blood brain barrier models

Name	Surname	Organisation	Country	E-mail address	Potential contribution to the project in terms of expertise, resources and activities.
Adianez	Obrador	Cuban Neurosciences Center	Mexico	adianez.obrador@cneuro.edu.cu	I would help finding the counterparts, working on the writing and management of the project
Inish	O'Doherty	1984	United States	iodoherty@c-path.org	Data management and analytics, project and public-private-partnership management
Javier	Oroz	CSIC	Spain	joroz@iqfr.csic.es	Structural biology of proteins related to misfolding diseases
Mazhar	Özkan	Tekirdağ Namık Kemal Üniversitesi Tıp Fakültesi	Turkey	ozkanmazhar@gmail.com	
Ferhat Can	Özkaya	SOLAB	Turkey	fcanozkaya@gmail.com	We would bring our experiments about isolation and elucidation of new antimicrobial chemical entities from microbial organisms
Irantzu	Pallares	Universitat Auonoma de Barcelona	Spain	irantzu.pallares@uab.cat	In our research group we work developing small molecules to halt a-synuclein aggregation and to PD diagnostic
Dulce	Papy-Garcia	UPEC	France	papy@u-pec.fr	Expertise in glycobiology, neurodegenerative disease. Cell culture, biochemistry, molecular biology, OMICS, histology.
Patricia	Pérez Librero	Spanish Federation of Parkinson's Disease	Spain	e-salud@esparkinson.es	As the only umbrella organization of Parkinson's disease (PD) in Spain, we bring more tahn 20 years of expertise in PD community

Name	Surname	Organisation	Country	E-mail address	Potential contribution to the project in terms of expertise, resources and activities.
Art	Petronis	Life Sciences Center, Vilnius University	Lithuania	art.petronis@camh.ca	Expertise in epigenomic studies of human disease, a chronoepigenetic origin of aging and neurodegeneration.
Claudia	Pfander	ARTTIC SAS	Germany	pfander@arttic.eu	project management expert, communication & dissemination, industry liaison in the field of ND,
Isabelle	Philippe	CEA	France	isabelle.philippe@cea.fr	Quantification of CSF tau by High-Resolution MS - PET and MRI - proteomics unbiased approach
Fabrizio	Piazza	University of Milano -Bioccca	Italy	fabrizio.piazza@unimib.it	Cohort of cerebral amyloid angiopathy (CAA) & related inflammation, including Plasma-MRI-CSF-PET- 5y longitudinal sampling.
Diana	Pirjol	HDS	Romania	dpirjol@human-datascience.org	
Irene	Pitsillidou	EULAR, CYPRUSV LEAGUE AGAINSTRHEUMATISM	Cyprus	roulla810@live.com	My knowledge and expertise working voluntarily for 13 years for my organisation and as a EULAR'S PRP since 2010
Haritz	Plazaola	IDIBAPS	Spain	PLAZAOLA@clinic.cat	
Santi	Rello-Varona	IdiPAZ institute	Spain	international.projects@idipaz.es	We are a Hospital, we can bring patients and clinical research expertise.
Vassiliki	Rentoumi	LANGAWARE	Greece	vassiliki@langaware.com	LangAware brings its experience in language and speech analysis employing AI and ML in the context of neurodegenerative diseases

Name	Surname	Organisation	Country	E-mail address	Potential contribution to the project in terms of expertise, resources and activities.
Ester	Rodriguez	Bellvitge Biomedical Research Institute - IDIBELL	Spain	ester.rodriguez@idibell.cat	stem cells, IPS, organoids
Viviana	Roman	Institute of Virology-Center of Immunology	Romania	rviviana30@yahoo.com	
Patrick	Ruch	SIB	Switzerland	patrick.ruch@hesge.ch	Neural language models to generate hypothesis related to cortex development
Agustín	Ruiz	Fundació ACE. Institut Català de Neurociències Aplicades	Spain	aruiz@fundacioace.org	Clinical and biomedicine knowledge and biomaterials
Ana María	Sánchez-Pérez	universitat Jaume I	Spain	sanchean@uji.es	experience in animal models and biotechnological tools (cloning AAV and shRNA); animal facilities, cell culture and microbiology
Raquel	Sanchez-Valle	Hospital Clínic de Barcelona/IDIBAPS	Spain	rsanchez@clinic.cat	biobanking, biological samples, clinical expertise, behavioural neurology
Maria Grazia	Santagati	sc	Italy	mariagrazia.santagati@tin.it	
M.	Schulte	LifeGlimmer GmbH	Germany	schulte@lifeglimmer.com	

Name	Surname	Organisation	Country	E-mail address	Potential contribution to the project in terms of expertise, resources and activities.
Mark	Sefton	Biomedred SL	Spain	mark@biomedred.com	expertise in project management, dissemination and communication
Ivan	Serina	University of Brescia	Italy	ivan.serina@unibs.it	Expert of Artificial Intelligence
Nir	Shaked	ISERD Israel Innovation Authority	Israel	nir.s@iserd.org.il	
Sudhir	Sivakumaran	Critical Path Institute	United States	ssivakumaran@c-path.org	Alzheimer's disease, data sharing, biomarker, quantitative tools, interoperability, data governance, data sharing principles
David	Smets	Icometrix	Belgium	david.smets@icometrix.com	discovery, validation and clinical implementation of neuro imaging biomarkers
Montserrat	Sole Castellvi	IBB_UAB	Spain	montserrat.sole.castellvi@uab.cat	Expertise in protein folding, misfolding and aggregation. Design and produce novel and better protein-based biopharmaceuticals.
Aureli	Soria-Frisch	Starlab Barcelona SL (SME)	Spain	aureli.soria-frisch@starlab.es	Artificial Intelligence, Electrophysiology, Data Analysis, Digital Markers
Stamatios	Sotiropoulos	University of Nottingham	United Kingdom	ssothro@hotmail.com	Expertise in high-throughput neuroimage analysis, data sharing, best practices for standardised processing and dissemination
Marie	Stas	NCP Wallonie	Belgium	marie.stas@ncpwallonie.be	

Name	Surname	Organisation	Country	E-mail address	Potential contribution to the project in terms of expertise, resources and activities.
Carl	Steinbeisser	collaborate.eu	Germany	carl@collaborate.eu	Good track record in project management and proposal writing. Setup of collaboration platforms for your team.
Diane	Stephenson	Critical Path Institute	United States	dstephenson@c-path.org	We lead AD and PD consortia that have delivered on many of the aims outlined in this initiative. Industry partners overlap
Mireia	Tomàs	FISABIO	Spain	tomas_mirgin@gva.es	
Andrea	Trabocchi	Università degli Studi di Firenze	Italy	andrea.trabocchi@unifi.it	small molecule organic synthesis; MRI molecular probes; preclinical micro MRI facility at CISPIM, Univ. Florence
Dagmar	Václavíková	Masaryk University	Czech Republic	dagmar.vaclavikova@med.muni.cz	Research facilities, experts
Michelle	van der Schoot	Casa di Cura Privata del Policlinico	Italy	m.vanderschoot@ccppdezza.it	Research team on neurodegenerative diseases and rare diseases; ideal setting to test/validate health solutions and technologies
Willeke	van Roon-Mom	LUMC	Netherlands	w.vanroon@lumc.nl	Expertise on neurodegenerative disorders, biomarker development and therapy development
Mariangela	Vanalli	Lombardia Informatica / Università degli Studi di Roma-Tor Vergata	Italy	mariangelavanalli@gmail.com	
Salvador	Ventura	Universitat Autònoma de Barcelona	Spain	salvador.ventura@uab.es	A new method for detecting a-synuclein oligomers and fibrils with nanomolar sensitivity.

Name	Surname	Organisation	Country	E-mail address	Potential contribution to the project in terms of expertise, resources and activities.
Manuel	Vidal-Sanz	Universidad de Murcia	Spain	manuel.vidal@um.es	Expertise to screen in animal models of retinal degeneration neuroprotective compounds in neurodegenerative diseases
Klemens	Vierlinger	AIT	Austria	klemens.vierlinger@ait.ac.at	biomarker discovery and validation, epigenomics, immunomics, NGS, bioinformatics, data mining
Pieter Jelle	Visser	Amsterdam UMC	Netherlands	pj.visser@amsterdamumc.nl	Cohorts, data harmonisation, infrastructures
Daniel	Weibel	Research Development Office, Erasmus Medical Center, Rotterdam, NL	Netherlands	d.weibel@erasmusmc.nl	www.erasmusmc.nl
Antoine	Wellink	Radboud University	Netherlands	antoine.wellink@ru.nl	top level neuroscience and biomarker research using intense infrared and Terahertz radiation